News Listing

Investment in new headquarters forms part of ongoing company growth plans and supports Zyme’s continued success, following client base and team expansion

CHAIN Biotechnology Ltd and the German Cancer Research Center (DKFZ) have signed an agreement to collaborate on the development of therapeutic cancer vaccines for indications caused by Human Papillomavirus (HPV).

The 15-month program focuses on combining the expertise and knowledge of both parties to design and test the anti-tumour efficacy of CHAIN’s novel, orally administered HPV vaccine ...

NOTTINGHAM, UK – April 15, 2024 – IsomAb Ltd, a UK-based biotechnology company developing isoform-specific disease modifying antibody treatments for serious and life-threatening diseases, today announced the appointment of Dr Anker Lundemose to its Board of Directors, as an independent non-executive Director. This follows the recent closing of a £7.5 million Seed funding in late February.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, to develop and commercialize transplant monitoring products using Bio-Rad’s Droplet Digital™ PCR (ddPCR™) instruments and reagents.

Search Highlights

Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.

AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.

These high-quality tissue microarrays (TMAs) enable high-throughput analysis of a panel of tissue types recognized by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Each TMA features multiple normal tissue ...

HERCULES, Calif., and PITTSBURGH, Penn. — April 8, 2024 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader of life science research and clinical diagnostics products, today announces a collaboration with Allegheny Health Network (AHN), a western Pennsylvania–based integrated healthcare system. This research collaboration aims to generate clinical evidence across a range of cancer ...

HERCULES, Calif. — April 02, 2024 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.b), a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit. The assay expands the company’s Droplet Digital PCR (ddPCR™) offering for the oncology market, where highly ...

Antibodies Validated for Use with Bio-Rad’s Celselect Slides™ Enumeration Stain Kits to Enable Immunostaining of Captured Circulating Tumor Cells in Liquid Biopsy Samples.

Project will be a demonstration of how Ubiquigent’s DUB-centric platform can support the development of DUB inhibitors all the way from discovery through to clinical development.